Business
Olema Oncology to Present New Data on OP-1250 at 2021 San Antonio Breast Cancer Symposium
Interim pharmacokinetic, safety and tolerability, and preliminary efficacy data from Phase 1 dose escalation to be presented Company to host investor webcast
About this update from Olema Pharmaceuticals, Inc.
[{"type":"text","content":"Interim pharmacokinetic, safety and tolerability, and preliminary efficacy data from Phase 1 dose escalation to be presented Company to host investor webcast at 8:30 a.m. ET on Wednesday, December 8, 2021 SAN FRANCISCO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced two poster presentations on OP-1250, an investigational complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) in development for the treatment of metastatic breast cancer and other women’s cancers, at the upcoming San Antonio Breast Cancer Symposium (SABCS) meeting being held December 7-10, 2021, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. “We look forward to sharing the first clinical data for OP-1250, our investigational complete estrogen receptor antagonist (CERAN), at SABCS, one of the most important medical meetings of the year for scientific exchange on advancing care for breast cancer,” said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. “These data, including pharmacokinetic, safety and tolerability, and preliminary efficacy, provide initial insights into the potential profile of OP-1250 in women living with advanced or metastatic ER+/HER2- breast cancer, an area where significant unmet need remains. We are encouraged by the emerging clinical profile of OP-1250, and believe it has the potential to become a differentiated, best-in-class endocrine therapy of choice for ER+ breast cancer.” Details of the poster presentations are as follows: Title: Preliminary data from a phase I/II, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer Presenter: Manish Patel, M.D., Florida Cancer Specialists/Sarah Cannon Research InstituteSession: Poster Session 1 (P1-17-12)Session Title: Treatment - Advanced Disease Treatment: Advanced Endocrine TherapySession Date: Wednesday, December 8, 2021; 7:00 a.m. CT Title: The complete estrogen receptor antagonist OP-1250 can combine with HER2 inhibition to inhibit estrogen receptor-driven cellular proliferation...